We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+23.92%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$579M
AUM Growth
+$205M
Cap. Flow
+$133M
Cap. Flow %
22.94%
Top 10 Hldgs %
77.06%
Holding
40
New
20
Increased
2
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$26M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$20.6M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.4M
4
HRMY icon
Harmony Biosciences
HRMY
+$11.9M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$11.5M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$8.85M
2
ARVN icon
Arvinas
ARVN
+$7.51M
3
APLS
Apellis Pharmaceuticals
APLS
+$4.73M
4
KROS icon
Keros Therapeutics
KROS
+$4.21M
5
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$2.26M

Sector Composition

Rank Sector Weight
1 Healthcare 96.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$171M 29.5%
2,503,059
-80,000
-3% -$4.73M
RCUS icon
2
Arcus Biosciences
RCUS
$3.57B
$69.8M 12.05%
2,668,316
-1,658
-0.1% -$43.8K
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$50.2M 8.66%
2,551,703
– –
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$38.6M 6.67%
624,500
+294,500
+89% +$20.6M
GOSS icon
5
Gossamer Bio
GOSS
$66.5M
$24.5M 4.23%
2,045,442
-712,627
-26% -$8.85M
TNDM icon
6
Tandem Diabetes Care
TNDM
$1.17B
$22.7M 3.92%
+474,929
New +$26M
CLDX icon
7
Celldex Therapeutics
CLDX
$2.77B
$21.4M 3.69%
761,398
– –
XBI icon
8
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$19.3M 3.33%
243,400
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.4M 2.66%
+221,000
New +$16.4M
VRNA
10
DELISTED
Verona Pharma
VRNA
$13.5M 2.34%
+1,324,868
New +$11.2M
VERA icon
11
Vera Therapeutics
VERA
$2.54B
$11.4M 1.96%
533,264
-41,736
-7% -$781K
HRMY icon
12
Harmony Biosciences
HRMY
$2.04B
$10.8M 1.86%
+243,500
New +$11.9M
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.3M 1.77%
+220,953
New +$11.5M
STOK icon
14
Stoke Therapeutics
STOK
$1.82B
$9.8M 1.69%
763,456
– –
BBIO icon
15
BridgeBio Pharma
BBIO
$16.5B
$9.28M 1.6%
933,743
– –
ALPN
16
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.82M 1.52%
+1,225,000
New +$10.1M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$8.62M 1.49%
+83,500
New +$7.92M
KRTX
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$7.76M 1.34%
+34,500
New +$6.98M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$36.3B
$7.47M 1.29%
+37,300
New +$7.11M
FATE icon
20
Fate Therapeutics
FATE
$281M
$7.42M 1.28%
+331,096
New +$9.57M
XLO icon
21
Xilio Therapeutics
XLO
$56.9M
$7.06M 1.22%
+173,214
New +$6.73M
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$6.2M 1.07%
379,629
+57,988
+18% +$1.11M
FDMT icon
23
4D Molecular Therapeutics
FDMT
$526M
$4.02M 0.69%
499,996
-132,749
-21% -$1.2M
NUVL
24
DELISTED
Nuvalent
NUVL
$3.89M 0.67%
+200,000
New +$3.35M
JNCE
25
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.28M 0.57%
+1,400,000
New +$4.96M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Octagon Capital Advisors held 40 positions worth $579M, up 55% from $375M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Octagon Capital Advisors deployed $133M of net new capital in Q3 2022, opening 20 new positions and adding to 2 existing holdings. Its largest new stake was Tandem Diabetes Care: 474,929 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Gossamer Bio, an estimated $8.85M trimmed.

  • Octagon Capital Advisors's largest Q3 2022 buy was Tandem Diabetes Care: 474,929 shares worth $22.7M.
  • Octagon Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $20.6M increase.
  • Octagon Capital Advisors's biggest Q3 2022 reduction was Gossamer Bio, cutting an estimated $8.85M.
  • Octagon Capital Advisors fully exited Arvinas in Q3 2022, selling an estimated $7.51M.
  • Octagon Capital Advisors's ten largest holdings make up 77% of its $579M portfolio in Q3 2022.
  • Octagon Capital Advisors opened 20 new positions and closed 5 in Q3 2022.
  • Octagon Capital Advisors's portfolio value rose 55% quarter-over-quarter to $579M.

Based on Octagon Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.